Kinetics and Thermodynamics of Ligand Binding by Cytochrome P450 3A4*
暂无分享,去创建一个
[1] A. P. Koley,et al. Cytochrome P450 conformation and substrate interactions as probed by CO binding kinetics. , 1996, Biochimie.
[2] H. Yamazaki,et al. Roles of divalent metal ions in oxidations catalyzed by recombinant cytochrome P450 3A4 and replacement of NADPH--cytochrome P450 reductase with other flavoproteins, ferredoxin, and oxygen surrogates. , 1995, Biochemistry.
[3] Jose Cosme,et al. Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone , 2004, Science.
[4] D. Waxman,et al. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. , 1986, The Journal of biological chemistry.
[5] J. Derancourt,et al. Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. , 1989, Drug metabolism and disposition: the biological fate of chemicals.
[6] T. Omura,et al. THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.
[7] C. Williams,et al. A method for titrating oxygen-sensitive organic redox systems with reducing agents in solution. , 1969, Analytical biochemistry.
[8] A. P. Koley,et al. Drug-drug interactions: effect of quinidine on nifedipine binding to human cytochrome P450 3A4. , 1997, Biochemical pharmacology.
[9] J. Houston,et al. Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[10] M. Delaforge,et al. High affinity of ergopeptides for cytochromes P450 3A. Importance of their peptide moiety for P450 recognition and hydroxylation of bromocriptine. , 1994, European Journal of Biochemistry.
[11] F. Guengerich,et al. Cytochrome P-450 3A4: regulation and role in drug metabolism. , 1999, Annual review of pharmacology and toxicology.
[12] S. Sligar,et al. Twenty-five Years of P450cam Research , 1995 .
[13] S. D. Turner,et al. Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[14] Ann-Charlotte Egnell,et al. Predictive Models of CYP3A4 Heteroactivation: In Vitro-in Vivo Scaling and Pharmacophore Modeling , 2005, Journal of Pharmacology and Experimental Therapeutics.
[15] F. Guengerich,et al. Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. , 1993, Chemical research in toxicology.
[16] S. Sligar,et al. Homotropic cooperativity of monomeric cytochrome P450 3A4 in a nanoscale native bilayer environment. , 2004, Archives of biochemistry and biophysics.
[17] W. Atkins,et al. The thermodynamic landscape of testosterone binding to cytochrome P450 3A4: ligand binding and spin state equilibria. , 2005, Biochemistry.
[18] Smita S. Patel,et al. Kinetic analysis of macromolecules : a practical approach , 2003 .
[19] Eric F. Johnson,et al. The Structure of Human Microsomal Cytochrome P450 3A4 Determined by X-ray Crystallography to 2.05-Å Resolution* , 2004, Journal of Biological Chemistry.
[20] H. Yamazaki,et al. Lack of Electron Transfer from Cytochrome b5 in Stimulation of Catalytic Activities of Cytochrome P450 3A4 , 1996, The Journal of Biological Chemistry.
[21] R. Estabrook,et al. Spectral studies of drug interaction with hepatic microsomal cytochrome. , 1967, Molecular pharmacology.
[22] L. Wienkers,et al. Pyrene.pyrene complexes at the active site of cytochrome P450 3A4: evidence for a multiple substrate binding site. , 2002, Journal of the American Chemical Society.
[23] F. Guengerich,et al. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. , 2001, Chemical research in toxicology.
[24] M. Godejohann,et al. Testosterone 1β‐hydroxylation by human cytochrome P450 3A4 , 2004 .
[25] A. Fersht. Structure and mechanism in protein science , 1998 .
[26] Ortiz de Montellano,et al. Cytochrome P-450: Structure, Mechanism, and Biochemistry , 1986 .
[27] F. Guengerich,et al. Rate-limiting steps in oxidations catalyzed by rabbit cytochrome P450 1A2. , 2004, Biochemistry.
[28] F. Guengerich,et al. Reduction of cytochrome b5 by NADPH-cytochrome P450 reductase. , 2005, Archives of biochemistry and biophysics.
[29] A. Kappas,et al. 7,8-Benzoflavone stimulates the metabolic activation of aflatoxin B1 to mutagens by human liver. , 1978, Biochemical and biophysical research communications.
[30] Barry C. Jones,et al. DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS , 2004, Drug Metabolism and Disposition.
[31] G. Miller,et al. Binding and oxidation of alkyl 4-nitrophenyl ethers by rabbit cytochrome P450 1A2: evidence for two binding sites. , 2001, Biochemistry.
[32] W. Pryor. Cytochrome P450: Structure, mechanism, and biochemistry , 1996 .
[33] Wei Tang,et al. Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. , 2001, Current drug metabolism.
[34] N. Oppenheimer,et al. Structure and mechanism , 1989 .
[35] James R. Halpert,et al. Alanine-scanning Mutagenesis of a Putative Substrate Recognition Site in Human Cytochrome P450 3A4 , 1997, The Journal of Biological Chemistry.
[36] H. Yamazaki,et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.
[37] A. P. Koley,et al. Differential Mechanisms of Cytochrome P450 Inhibition and Activation by α-Naphthoflavone* , 1997, The Journal of Biological Chemistry.
[38] J. Ladbury. Application of isothermal titration calorimetry in the biological sciences: things are heating up! , 2004, BioTechniques.
[39] D. Ballou,et al. The use of protocatechuate dioxygenase for maintaining anaerobic conditions in biochemical experiments. , 2000, Analytical biochemistry.
[40] F. Guengerich,et al. Cytochrome P450 3A4-catalyzed Testosterone 6β-Hydroxylation Stereochemistry, Kinetic Deuterium Isotope Effects, and Rate-limiting Steps* , 2005, Journal of Biological Chemistry.
[41] Slobodan Petar Rendic. Summary of information on human CYP enzymes: human P450 metabolism data , 2002, Drug metabolism reviews.
[42] T. Baillie,et al. A Kinetic Model for the Metabolic Interaction of Two Substrates at the Active Site of Cytochrome P450 3A4* , 2001, Journal of Biological Chemistry.
[43] D. Greenblatt,et al. Five Distinct Human Cytochromes Mediate Amitriptyline N‐Demethylation In Vitro: Dominance of CYP 2C19 and 3A4 , 1998, Journal of clinical pharmacology.
[44] T. Shimada,et al. Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[45] F. Guengerich,et al. Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. , 1993, Archives of biochemistry and biophysics.
[46] F. Guengerich,et al. Kinetic Analysis of Oxidation of Coumarins by Human Cytochrome P450 2A6* , 2005, Journal of Biological Chemistry.
[47] P. Hollenberg,et al. Role of the alanine at position 363 of cytochrome P450 2B2 in influencing the NADPH- and hydroperoxide-supported activities. , 1998, Archives of biochemistry and biophysics.
[48] G. Miller,et al. Elucidation of distinct ligand binding sites for cytochrome P450 3A4. , 2000, Biochemistry.
[49] S. Ekins,et al. Examination of purported probes of human CYP2B6. , 1997, Pharmacogenetics.
[50] J. Halpert,et al. Analysis of homotropic and heterotropic cooperativity of diazepam oxidation by CYP3A4 using site-directed mutagenesis and kinetic modeling. , 2003, Archives of biochemistry and biophysics.
[51] K. Korzekwa,et al. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. , 1994, Biochemistry.
[52] S. Sligar,et al. Temperature-dependent spin equilibrium of microsomal and solubilized cytochrome P-450 from rat liver. , 1979, Biochemistry.
[53] T. Tracy,et al. Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[54] J. Halpert,et al. Molecular basis of P450 inhibition and activation: implications for drug development and drug therapy. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[55] S. Ekins,et al. Autoactivation and activation of the cytochrome P450s. , 1998, International journal of clinical pharmacology and therapeutics.
[56] S. Sligar,et al. Kinetics of dithionite-dependent reduction of cytochrome P450 3A4: heterogeneity of the enzyme caused by its oligomerization. , 2005, Biochemistry.
[57] P. Kuzmič,et al. Program DYNAFIT for the analysis of enzyme kinetic data: application to HIV proteinase. , 1996, Analytical biochemistry.
[58] J. Halpert,et al. Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[59] F. Guengerich,et al. Kinetics of ferric cytochrome P450 reduction by NADPH-cytochrome P450 reductase: rapid reduction in the absence of substrate and variations among cytochrome P450 systems. , 1997, Biochemistry.
[60] A. Conney,et al. Activation of monooxygenases in human liver by 7,8‐benzoflavone , 1977, Clinical pharmacology and therapeutics.
[61] T. Tracy,et al. Atypical kinetic profiles in drug metabolism reactions. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[62] B. Griffin,et al. Camphor binding by Pseudomonas putida cytochrome P-450. Kinetics and thermodynamics of the reaction. , 1972, Biochemistry.
[63] M. Shou. Kinetic analysis for multiple substrate interaction at the active site of cytochrome P450. , 2002, Methods in enzymology.
[64] D. Dunbar,et al. Characterization of human small intestinal cytochromes P-450. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[65] D. Stewart,et al. HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes. , 1997, Toxicology letters.
[66] J. Halpert,et al. Structures of cytochrome P450 3A4. , 2005, Trends in biochemical sciences.
[67] A. Y. Lu,et al. Allosteric behavior in cytochrome p450-dependent in vitro drug-drug interactions: a prospective based on conformational dynamics. , 2001, Chemical research in toxicology.
[68] Aleksandra Galetin,et al. Modelling atypical CYP3A4 kinetics: principles and pragmatism. , 2005, Archives of biochemistry and biophysics.
[69] F. Guengerich,et al. Cooperativity in oxidations catalyzed by cytochrome P450 3A4. , 1997, Biochemistry.
[70] J. Halpert,et al. Influence of P450 3A4 SRS-2 residues on cooperativity and/or regioselectivity of aflatoxin B(1) oxidation. , 2001, Chemical research in toxicology.